Author: MarketBeat

First Interstate Bank increased its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB - Free Report) by 1.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,322 shares of the financ

SG Americas Securities LLC raised its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR - Free Report) by 1,675.7% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 118,317 shares of the company's stock after acquiring an additional 111,654 shares during

Northwestern Mutual Wealth Management Co. trimmed its holdings in iShares Biotechnology ETF (NASDAQ:IBB - Get Rating) by 2.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 40,414 shares of the financial services provider

B. Riley Wealth Advisors Inc. boosted its stake in shares of iShares Biotechnology ETF (NASDAQ:IBB - Get Rating) by 25.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,068 shares of the financ

Sana Biotechnology, Inc. (NASDAQ:SANA - Get Rating) major shareholder Ventures Fund V. Gener Flagship sold 82,000 shares of the business's stock in a transaction that occurred on Friday, May 26th. The stock was sold at an average price of $6.23, for a total transaction of $510,860.00. Following the completion of the transaction, the insider now owns 1,425,334 shares in the company, valued at approximately $8,879,830.82. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own at least 10% of a company's stock are required to disclose their transactions with the SEC.

Pier Capital LLC lowered its stake in Cerus Co. (NASDAQ:CERS - Get Rating) by 22.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,351,218 shares of the biotechnology company's stock after selling 380,161

Marathon Capital Management purchased a new stake in shares of iShares Biotechnology ETF (NASDAQ:IBB - Get Rating) in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm purchased 4,015 shares of the financial services prov

WINTON GROUP Ltd boosted its stake in Vir Biotechnology, Inc. (NASDAQ:VIR - Get Rating) by 20.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 57,642 shares of the company's stock after acquiring an additio